Exploring FCGR3A: A Protein Involved in Many Immune and Clotting Functions

Target Name: FCGR3A

NCBI ID: G2214

FCGR3A

Exploring FCGR3A: A Protein Involved in Many Immune and Clotting Functions

FCGR3A, also known as IgG Fc receptor III-2, is a protein that is expressed in many tissues throughout the body, including the skin, hair, and nails. It is a type of Fc receptor, which is a type of protein that is found on the surface of many different types of cells in the body. Fc receptors are involved in many different functions in the body, including immune responses and blood clotting.

One of the things that makes FCGR3A an interesting potential drug target is its role in the immune system. The Fc receptor is a key part of the immune system, as it helps to recognize and respond to foreign substances that enter the body. In particular, FCGR3A is involved in the activation of T cells, which are a type of immune cell that play a key role in fighting off infections and diseases.

Another potential drug target for FCGR3A is its role in blood clotting. Fc receptors are also involved in blood clotting, as they help to regulate the formation of blood clots. This is important because blood clots can be a serious risk factor for many different diseases, including heart attack and stroke.

In addition to its role in the immune system and blood clotting, FCGR3A is also involved in many other different functions in the body. For example, it is involved in the regulation of cell growth and differentiation, and it is also involved in the development and maintenance of tissues.

Overall, FCGR3A is a protein that is involved in many important functions in the body, and it is a potential drug target for many different diseases. If its potential drug targets are identified and validated, it could be a valuable tool for the development of new treatments for a wide range of conditions.

Protein Name: Fc Gamma Receptor IIIa

Functions: Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger (PubMed:24412922, PubMed:25786175, PubMed:21768335, PubMed:22023369, PubMed:8609432, PubMed:9242542, PubMed:25816339, PubMed:11711607, PubMed:28652325). Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC (PubMed:25786175, PubMed:24412922). Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis (PubMed:9916693, PubMed:29967280). Fc-binding subunit that associates with CD247 and/or FCER1G adapters to form functional signaling complexes. Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation (PubMed:2532305, PubMed:1825220, PubMed:23024279). Costimulates NK cells and trigger lysis of target cells independently of IgG binding (PubMed:23006327, PubMed:10318937). Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells (PubMed:27670158). Mediates enhanced ADCC in response to afucosylated IgGs (PubMed:34485821)

The "FCGR3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCGR3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets